Skip to main content

Oncology Value Sets

NeoplasmObservationVS

Description TBD

Code Display CodeSystem
All codes descending from 108369006 Neoplasm (morphologic abnormality) http://snomed.info/sct

NeoplasmObservationMethodVS

Description TBD

Code Display CodeSystem
All codes descending from 386053000 Evaluation ProcedurePerformed http://snomed.info/sct

BreastCancerTypeVS

Description TBD

Code Display CodeSystem
All codes descending from 126926005 Neoplasm of the breast (disorder) http://snomed.info/sct

ReceptorVS

Description TBD

Code Display CodeSystem
All codes descending from 116647005 Receptor (substance) http://snomed.info/sct

StainingIntensityVS

Part of the Allred scoring, based on the intensity of that staining, on a scale of 0 (Negative) to 3 (Strong).

Code Display CodeSystem
29915 None/Negative https://sdt.cap.org
29811 Weak https://sdt.cap.org
29812 Moderate https://sdt.cap.org
29914 Strong https://sdt.cap.org

StainingControlVS

Staining of control cells, required if staining is negative.

Code Display CodeSystem
25896 Internal control cells present and stain as expected https://sdt.cap.org
25898 Internal control cells absent. https://sdt.cap.org
32089 Internal control cells present; no immunoreactivity of either tumor cells or internal controls https://sdt.cap.org

NottinghamCombinedGradeVS

Description TBD

Code Display CodeSystem
369790002 Low grade or well differentiated http://snomed.info/sct
369791003 Intermediate/moderate grade or moderately differentiated http://snomed.info/sct
369792005 High grade or pooly differentiated http://snomed.info/sct

LymphSystemSubdivisionVS

A lymph node area or nodal group; a subdivision of the entire lymphatic system. For breast cancer, this includes 5 areas: internal mammary lymph nodes, axillary lymph nodes level I, II, and III, and the supraclavicular lymph nodes.

Code Display CodeSystem
All codes descending from 122490001 Lymphoid system structure (body structure) http://snomed.info/sct

HER2MethodVS

Description TBD

Code Display CodeSystem
single HER2 by Single Probe Assay In SituHybridization test HER2MethodCS
dual HER2 by Dual Probe Assay In SituHybridization test HER2MethodCS
ihc HER2 by ImmunoHistochemistry HER2MethodCS

DegreeOfLymphaticInvolvementVS

Description TBD

Code Display CodeSystem
microscopic Only a few cancer cells are in the node. DegreeOfLymphaticInvolvementCS
gross The cancer can be seen or felt without aid of microscopy. DegreeOfLymphaticInvolvementCS
extracapsular Cancer has pread outside the wall of the node. DegreeOfLymphaticInvolvementCS

GeneIdentifierVS

A unique code for a gene, including protein coding genes, ncRNA genes and pseudogenes, to allow unambiguous communication, drawn from HUGO Gene Nomenclature Committee.

Code Display CodeSystem
All codes found in CodeSystem http://www.genenames.org http://www.genenames.org http://www.genenames.org

RefseqVS

Description TBD

Code Display CodeSystem
All codes found in CodeSystem https://www.ncbi.nlm.nih.gov/refseq https://www.ncbi.nlm.nih.gov/refseq https://www.ncbi.nlm.nih.gov/refseq

DecileVS

Division of percentages into 10% intervals.

Code Display CodeSystem
0_10 0 to 10% DecileCS
11_20 11 to 20% DecileCS
21_30 21 to 30% DecileCS
31_40 31 to 40% DecileCS
41_50 41 to 50% DecileCS
51_60 51 to 60% DecileCS
61_70 61 to 70% DecileCS
71_80 71 to 80% DecileCS
81_90 81 to 90% DecileCS
91_100 91 to 100% DecileCS

CertifiedByVS

Who has certified or cleared a test, device, or drug for use.

Code Display CodeSystem
31090 US Food and Drug Administration https://sdt.cap.org
32779 Health Canada https://sdt.cap.org
31091 Not certified; laboratory-developed test https://sdt.cap.org
32779 Other non-US based health system. https://sdt.cap.org

EstrogenAntibodyVS

Antibodies relevant to Estrogen receptor.

Code Display CodeSystem
31093 SP1 https://sdt.cap.org
31094 6F11 https://sdt.cap.org
31095 1D5 https://sdt.cap.org

ProgesteroneAntibodyVS

Antibodies relevant to Estrogen receptor.

Code Display CodeSystem
31103 1E2 https://sdt.cap.org
31104 636 https://sdt.cap.org
31105 16 https://sdt.cap.org
31097 SP2 https://sdt.cap.org
31098 1A6 https://sdt.cap.org
32115 1294 https://sdt.cap.org
32116 312 https://sdt.cap.org

HER2StatusVS

HER2 status overall result

Code Display CodeSystem
31015 Negative/Not Amplified (IHC Score 0) https://sdt.cap.org
31016 Negative (IHC Score 1+) https://sdt.cap.org
31017 Equivocal (ICHC Score 2+) https://sdt.cap.org
31018 Positive/Amplified (IHC Score 3+) https://sdt.cap.org
25883 Cannot be determined (indeterminate) https://sdt.cap.org

HER2AntibodyIHCVS

Antibodies relevant to HER2 receptor (IHC Test).

Code Display CodeSystem
31117 4B5 https://sdt.cap.org
31118 HercepTest https://sdt.cap.org
31119 A0485 https://sdt.cap.org
31120 SP3 https://sdt.cap.org
31121 CB11 https://sdt.cap.org

Ki67AntibodyVS

Antibodies relevant to Ki-67 Text.

Code Display CodeSystem
31125 MIB1 https://sdt.cap.org
31126 SP6 https://sdt.cap.org
32169 MM1 https://sdt.cap.org
32160 30-9 https://sdt.cap.org
32168 IR / IS626 https://sdt.cap.org

TumorMarginDescriptionVS

Description TBD

Code Display CodeSystem
129738007 Lesion with circumscribed margin http://snomed.info/sct
129741003 Lesion with indistinct margin http://snomed.info/sct
129739004 Lesion with microlobulated margin http://snomed.info/sct
129740002 Lesion with obscured margin http://snomed.info/sct
129742005 Lesion with spiculated margin http://snomed.info/sct

StagingMethodVS

The methodology or standard used to do the staging.

Code Display CodeSystem
ajcc_v7 AJCC Breast Carcinoma Version 7 StagingMethodCS
ajcc_v8 AJCC Breast Carcinoma Version 8 StagingMethodCS

StagingTimeVS

When staging was done, relative to treatment events.

Code Display CodeSystem
clinical On initial diagnosis StagingTimeCS
pathologic Post-operative, after resection surgery StagingTimeCS
enrollment When patient is enrolled in a clinical trial StagingTimeCS
recurrence Upon recurrence of disease StagingTimeCS

TubuleFormationScoreVS

Description TBD

Code Display CodeSystem
369778004 Breast tubule formation: Majority of tumor >75% (score = 1) http://snomed.info/sct
369779007 Breast tubule formation: Moderate 10% to 75% (score = 2) http://snomed.info/sct
369780005 Breast tubule formation: Minimal <10% (score = 3) http://snomed.info/sct

NuclearPleomorphismScoreVS

Description TBD

Code Display CodeSystem
384735004 Nuclear pleomorphism: small regular nuclei (score=1) http://snomed.info/sct
384737007 Nuclear pleomorphism: moderate increase in size, etc (score = 2) http://snomed.info/sct
384738002 Nuclear pleomorphism: marked variation in size, nucleoli, chromatin clumping, etc (score = 3) http://snomed.info/sct

BrcaReceptorStatusVS

Classification of receptor status in breast cancer.

Code Display CodeSystem
luminal_A Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy. BrcaReceptorStatusCS
luminal_B Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2. BrcaReceptorStatusCS
HER2_positive Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2. BrcaReceptorStatusCS
Triple_negative Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy. BrcaReceptorStatusCS